AbbVie M19-130

Brief description of study

The purpose of this study is to see if the study drugs, elsubrutinib (ABBV-105), upadacitinib (ABT-494), or both elsubrutinib (ABBV-105) and upadacitinib (ABT-494) in combination (ABBV-599) are safe, tolerable, and effective in treating moderately to severely active systemic lupus erythematosus (SLE).


Clinical Study Identifier: s19-01634
ClinicalTrials.gov Identifier: NCT03978520
Principal Investigator: Amit Saxena.
Other Investigator: Janine M. Sullivan.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.